ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Quarterly Earnings Results, Beats Estimates By $1.48 EPS

ACADIA Pharmaceuticals (NASDAQ:ACAD) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $1.48, FiscalAI reports. The company had revenue of $298.00 million during the quarter, compared to analysts’ expectations of $292.54 million. ACADIA Pharmaceuticals had a return on equity of 13.96% and a net margin of 36.49%.The business’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business earned $0.86 earnings per share.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

• Acadia reported a milestone year with adjusted 2025 revenues of $1.08 billion (Q4 adjusted revenues of $298M), provided 2026 total revenue guidance of $1.22–$1.28B, and ended 2025 with $820M in cash.
• NUPLAZID momentum continued with Q4 adjusted net sales of $189M (volume +13% Q/Q) and the company guided 2026 net sales to $760–$790M, reaffirming a path toward ~$1B annual sales by 2028.
• DAYBUE STIX (FDA‑approved powder formulation) has shown early caregiver/HCP interest; DAYBUE delivered Q4 net sales of $110M and management expects 2026 global net sales of $460–$490M, with an estimated incremental opportunity of ~400+ patients over 2–3 years.
• The CHMP issued a negative trend vote on trofinetide (DAYBUE) in the EU; Acadia plans to request a reexamination (~120 days), creating near‑term regulatory uncertainty and the company excluded potential EU commercial sales from 2026 guidance.
• Key R&D catalyst — top‑line Phase 2 results for remlifanserin in Alzheimer’s disease psychosis are expected in August–October 2026, and the company cites ~$4 billion peak sales potential for remlifanserin across targeted indications.

ACADIA Pharmaceuticals Stock Up 1.6%

Shares of NASDAQ:ACAD traded up $0.40 during midday trading on Friday, reaching $25.04. The company had a trading volume of 211,174 shares, compared to its average volume of 1,456,600. The business’s 50 day moving average price is $25.58 and its 200 day moving average price is $24.45. ACADIA Pharmaceuticals has a 1-year low of $13.40 and a 1-year high of $28.35. The stock has a market cap of $4.24 billion, a PE ratio of 10.96, a P/E/G ratio of 8.73 and a beta of 0.66.

Analysts Set New Price Targets

A number of brokerages have weighed in on ACAD. Mizuho raised shares of ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $29.00 to $35.00 in a research note on Monday. Wall Street Zen downgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. JPMorgan Chase & Co. lowered their target price on shares of ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a research note on Monday, November 17th. Oppenheimer restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Friday, February 6th. Finally, Wolfe Research initiated coverage on ACADIA Pharmaceuticals in a research note on Monday. They issued an “outperform” rating and a $33.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.74.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat and 2026 revenue guidance — Acadia delivered an EPS beat and ~9% y/y revenue growth, reported >$1B in annual revenue, and set 2026 revenue guidance of roughly $1.22B–$1.28B, supporting the company’s growth narrative. Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
• Positive Sentiment: Analyst price-target raises from some shops — TD Cowen and Citizens JMP raised price targets (TD Cowen to $37; Citizens JMP to $35), signaling continued buy-side confidence in Acadia’s commercial momentum. Benzinga coverage of analyst moves
• Neutral Sentiment: Earnings call and transcripts now available — detailed commentary on DAYBUE, NUPLAZID uptake and pipeline progress (DAYBUE STIX, trofinetide programs) will inform investors but are descriptive rather than immediately market-moving. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Short-interest data in feeds shows anomalous/zero values (likely reporting noise) and is not a reliable driver of today’s action.
• Negative Sentiment: HC Wainwright trimmed its Q3 and Q4 2026 EPS estimates (Q3 to $0.16, Q4 to $0.23) despite keeping a Buy rating and $37 target — downward EPS revisions can pressure sentiment even when the long-term view remains positive.
• Negative Sentiment: Product/regulatory uncertainty — coverage flagged a trofinetide EU setback and a slight sales miss nuance that cloud the mid‑cycle growth outlook for certain pipeline/label expansion items. Zacks: Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
• Negative Sentiment: Some analysts trimmed targets or ratings — Stifel cut its target to $24 (Hold) and RBC trimmed its target to $30 (still Outperform), adding mixed messages that can create near-term selling pressure. Benzinga coverage of analyst moves

Insider Activity

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $23.38, for a total transaction of $162,491.00. Following the sale, the executive vice president owned 7,609 shares in the company, valued at $177,898.42. This represents a 47.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 26.50% of the stock is currently owned by corporate insiders.

Institutional Trading of ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC grew its position in shares of ACADIA Pharmaceuticals by 2,052.1% in the 3rd quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company’s stock valued at $31,652,000 after acquiring an additional 1,414,315 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in ACADIA Pharmaceuticals by 390.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company’s stock worth $35,187,000 after purchasing an additional 1,312,426 shares during the period. Logos Global Management LP acquired a new position in ACADIA Pharmaceuticals during the fourth quarter worth approximately $22,704,000. State Street Corp raised its stake in ACADIA Pharmaceuticals by 9.0% in the fourth quarter. State Street Corp now owns 7,910,733 shares of the biopharmaceutical company’s stock valued at $211,296,000 after buying an additional 655,257 shares during the period. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of ACADIA Pharmaceuticals in the second quarter valued at approximately $13,024,000. 96.71% of the stock is owned by institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.